Systemic perturbation of the ERK signaling pathway by the proteasome inhibitor, MG132.
Inhibition of the ubiquitin-proteasome protein degradation pathway has been identified as a viable strategy for anti-tumor therapy based on its broad effects on cell proliferation. By the same token, the variety of elicited effects confounds the interpretation of cell-based experiments using proteas...
Main Authors: | Murat Cirit, Kyle G Grant, Jason M Haugh |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3511445?pdf=render |
Similar Items
-
Effects of proteasome inhibitor MG-132 on the parasite Schistosoma mansoni.
by: Enyara R Morais, et al.
Published: (2017-01-01) -
The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease
by: Inoue, Satoko
Published: (2010) -
Stability of zinc finger nuclease protein is enhanced by the proteasome inhibitor MG132.
by: Suresh Ramakrishna, et al.
Published: (2013-01-01) -
The proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in mice
by: Trensz Frédéric, et al.
Published: (2011-08-01) -
Mechanisms of the proteasome inhibitor MG132-induced apoptosis in K562-leukemia cells
by: Tung Hui Chao, et al.
Published: (2014)